Tumor immunotherapies, especially those leveraging T-cells to identify and eliminate cancer cells, represent a major breakthrough in cancer treatment. However, many tumor-associated antigens are not expressed at a high enough density on the cancer cell surface to effectively activate T-cells, and these antigens are often present at low levels in normal tissues, leading to poor treatment specificity and potential off-target toxic side effects.

A research team from the Department of Pathology at the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) has discovered that atorvastatin, a widely used cholesterol-lowering drug, could become a powerful new weapon in the fight against liver cancer.

A simple AI model has been shown to perform on a par with experienced dermatologists when assessing the aggressiveness of a common form of skin cancer, squamous cell carcinoma. The research was headed by the University of Gothenburg.